ArticlePloS one2015
Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review.International journal of molecular sciences · 2020Pooled it
- Biomarker concordance between primary colorectal cancer and its metastases.EBioMedicine · 2019Pooled it
- Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.Journal of translational medicine · 2026Review
- In Silico Analysis of the Dual Role of Tumor Microenvironment on Colon Cancer Subtypes.Cancer informatics · 2026Article
- The plakin family: Potential therapeutic targets for digestive system tumors.Journal of translational internal medicine · 2025Article
- Utilization of primary tumor samples for cancer neoantigen discovery.Journal for immunotherapy of cancer · 2025Article
- Spatially ResolvedbioRxiv : the preprint server for biology · 2024Article
- Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications.Cancers · 2023Review
- Comparison of genetic variation between primary colorectal cancer and metastatic peritoneal cancer.Genes & genomics · 2023Article
- Biomarker concordance between primary colorectal cancer and ovarian metastases: a Dutch cohort study.Journal of cancer research and clinical oncology · 2023Article
- Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Somatic targeted mutation profiling of colorectal cancer precursor lesions.BMC medical genomics · 2022Article
- Recommendations for Specimen and Therapy Selection in Colorectal Cancer.Oncology and therapy · 2021Article
- Article
- Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?Translational oncology · 2021Review
- G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer.British journal of cancer · 2021Article
- Role of RASA1 in cancer: A review and update (Review).Oncology reports · 2020Review
- Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer.Cancers · 2019Review
- Repurposing EGFR Inhibitor Utility in Colorectal Cancer in MutantCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
introductionMetastasis is thought to be a clonal event whereby a single cell initiates the development of a new tumor at a distant site. However the degree to which primary and metastatic tumors differ on a molecular level remains unclear. To further evaluate these concepts, we used next generation sequencing (NGS) to assess the molecular composition of paired primary and metastatic colorectal cancer tissue specimens.
methods468 colorectal tumor samples from a large personalized medicine initiative were assessed by targeted gene sequencing of 1,321 individual genes. Eighteen patients produced genomic profiles for 17 paired primary:metastatic (and 2 metastatic:metastatic) specimens.
resultsAn average of 33.3 mutations/tumor were concordant (shared) between matched samples, including common well-known genes (APC, KRAS, TP53). An average of 2.3 mutations/tumor were discordant (unshared) among paired sites. KRAS mutational status was always concordant. The overall concordance rate for mutations was 93.5%; however, nearly all (18/19 (94.7%)) paired tumors showed at least one mutational discordance. Mutations were seen in: TTN, the largest gene (5 discordant pairs), ADAMTS20, APC, MACF1, RASA1, TP53, and WNT2 (2 discordant pairs), SMAD2, SMAD3, SMAD4, FBXW7, and 66 others (1 discordant pair).
conclusionsWhereas primary and metastatic tumors displayed little variance overall, co-evolution produced incremental mutations in both. These results suggest that while biopsy of the primary tumor alone is likely sufficient in the chemotherapy-naïve patient, additional biopsies of primary or metastatic disease may be necessary to precisely tailor therapy following chemotherapy resistance or insensitivity in order to adequately account for tumor evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.